Market Research Logo

Global Colorectal Cancer Drugs Market 2015-2019

Global Colorectal Cancer Drugs Market 2015-2019

About Colorectal Cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories:

  • Biologics
  • Small molecules
Based on the route of administration, the market is grouped into two categories:
  • Oral
  • Parenteral
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
  • Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
  • EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
  • APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
  • Americas
  • APAC
  • EMEA
Key Vendors
  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Serono
Other Prominent Vendors
  • Accord Healthcare
  • Advenchen Laboratories
  • Aeterna Zentaris
  • AstraZeneca
  • Bavarian Nordic
  • Biothera
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Debiopharm
  • Eisai
  • Eli Lilly
  • Immodulon Therapeutics
  • Mologen
  • Mylan
  • Nektar Therapeutics
  • Oncothyreon
  • Otsuka Pharmaceutical
  • Precision Biologics
  • Sun Pharmaceutical
  • Symphogen
  • Taiho
  • Takeda
  • Teva
  • ThromboGenics
  • Xbiotech
  • Yakult Honsha
Market Driver
  • Increase in population of patients
  • For a full, detailed list, view our report
Market Challenge
  • Loss of patent exclusivity
  • For a full, detailed list, view our report
Market Trend
  • Dominance of biologics
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
    • Pathophysiology
    • Epidemiology
    • Diagnosis
      • Table Diagnosis of Colorectal Cancer
    • Staging
      • Staging: Colon Cancer
      • Staging: Rectal Cancer
    • Management
      • Table Treatment and Management of Colorectal Cancer
    • Economic Burden
      • Table Economic Burden of Colorectal Cancer
  • Market Landscape
    • Market Overview
      • Table Snapshot of Global Colorectal Cancer Drugs Market
    • Market Size and Forecast
      • Table Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in US
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in Germany
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in Spain
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in Japan
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in China
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Type of Molecules
    • Table Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
    • Small Molecules
    • Biologics
      • Table Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules 2014
  • Market Segmentation by Route of Administration
    • Table Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
    • Oral
    • Parenteral
      • Table Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration 2014
  • Geographical Segmentation
    • Table Segmentation of Global Colorectal Cancer Drugs Market by Geography 2014
    • Market Size and Forecast
      • Table Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in Americas
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
    • Colorectal Cancer Drugs Market in EMEA
    • Colorectal Cancer Drugs Market in APAC
      • Market Size and Forecast
        • Table Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
        • Table Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014-2019
  • Key Leading Countries
    • US
    • Japan
    • Germany
    • Spain
    • China
  • Buying Criteria
  • Market Growth Drivers
    • Table Drivers of Global Colorectal Cancer Drugs Market
  • Drivers and their Impact
  • Market Challenges
    • Table Challenges for Vendors in Global Colorectal Cancer Drugs Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in Global Colorectal Cancer Drugs Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Analysis 2014
      • Competitive Assessment of Top Drugs for Colorectal Cancer
        • Table YoY Growth Rate of Major Colorectal Cancer Drugs 2010-2014 ($ millions)
      • F. Hoffmann-La Roche
        • Table F. Hoffmann-La Roche: Product Portfolio
        • Table Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
        • Table Avastin: Region-wise Revenues 2010-2014 ($ millions)
        • Table Avastin: YoY Revenues and Growth Rate in US 2010-2014 ($ millions)
        • Table Avastin: YoY Revenues and Growth Rate in Europe 2010-2014 ($ millions)
        • Table Avastin: YoY Revenues and Growth Rate in Japan 2010-2014 ($ millions)
        • Table Avastin: YoY International Revenues and Growth Rate of 2010-2014 (Except US, Europe, and Japan) ($ millions)
        • Table Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
        • Table Xeloda: Region-wise Revenues 2010-2014 ($ millions)
        • Table Xeloda: YoY Revenues and Growth Rate in US 2010-2014 ($ millions)
        • Table Xeloda: YoY Revenues and Growth Rate in Europe 2010-2014 ($ millions)
        • Table Xeloda: YoY Revenues and Growth Rate in Japan 2010-2014 ($ millions)
        • Table Xeloda: YoY International Revenues and Growth Rate 2010-2014 (Except US, Europe, and Japan) ($ millions)
      • Merck Serono
        • Table Merck Serono: Product Portfolio
        • Table Erbitux: Revenue and YoY Growth Rate Except US and Canada 2010-2014 ($ millions)
        • Table Erbitux: Region-wise Revenues 2012-2014 ($ millions)
        • Table Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
        • Table Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
        • Table Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
      • Bristol-Myers Squibb
        • Table Bristol-Myers Squibb: Product Portfolio
        • Table Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
      • Amgen
        • Table Amgen: Product Portfolio
        • Table Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
        • Table Vectibix: Region-wise Revenues 2010-2014 ($ millions)
      • Sanofi
        • Table Sanofi: Product Portfolio
        • Table Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
        • Table Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
        • Table Eloxatin: YoY Revenues and Growth Rate in US ($ millions)
        • Table Eloxatin: YoY Revenues and Growth Rate in Europe ($ millions)
        • Table Eloxatin: YoY Revenues and Growth Rate in Emerging Markets ($ millions)
        • Table Eloxatin: YoY Revenues and Growth Rate in ROW 2010-2014 ($ millions)
        • Table Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
        • Table Zaltrap: Region-wise Revenue 2013 and 2014 ($ millions)
      • Bayer
        • Table Bayer: Product Portfolio
        • Table Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
    • Other and Future Prominent Vendors
  • Key Takeaways
    • Table Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
  • Key Vendor Analysis
    • Amgen
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Amgen: Business Segmentation by Revenue 2013
      • Product Portfolio by Revenue 2013
        • Table Amgen: Product Portfolio by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Amgen: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Bayer
      • Key facts
      • Business overview
      • Business segmentation by revenue 2014
        • Table Bayer: Business segmentation by revenue 2014
      • Business segmentation by revenue 2013 and 2014
        • Table Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
      • Geographical segmentation by revenue 2014
        • Table Bayer: Geographical segmentation by revenue 2014
      • Business strategy
      • Recent developments
      • SWOT analysis
    • Bristol-Myers Squibb
      • Key Facts
      • Business Overview
      • Key Product Offerings
        • Table Bristol-Myers Squibb: Key Product Offerings (Based on Therapeutic Areas)
      • Revenue by Geography
        • Table Bristol-Myers Squibb: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Merck Serono
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Merck Serono: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Sanofi SA
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report